Recent pharmacological advances in the management of gout.
Rheumatology (Oxford)
; 57(6): 951-958, 2018 Jun 01.
Article
em En
| MEDLINE
| ID: mdl-28968896
ABSTRACT
Gout is the most common cause of inflammatory arthritis worldwide, and reports show that despite availability of therapies, management is still suboptimal. The new EULAR 2016 recommendations for the treatment of gout highlight the huge development in gout therapies, and the number of drugs being trialled only continues to increase. A clinical review of the evidence that underlies the recommendations from EULAR can reveal possible gaps in the literature and avenues for future research into gout therapies.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Supressores da Gota
/
Medicina Baseada em Evidências
/
Gerenciamento Clínico
/
Gota
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Revista:
Rheumatology (Oxford)
Assunto da revista:
REUMATOLOGIA
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Reino Unido